目的：探讨康柏西普联合微脉冲激光(SML)治疗糖尿病性黄斑水肿(DME)的疗效评估及其对黄斑区血流灌注、视觉功能的影响。

方法：回顾性研究。选取2023年6月至2024年12月本院收治的DME患者70例，根据治疗方案不同分为两组，其中接受康柏西普治疗的35例患者为对照组，接受康柏西普联合SML治疗的35例患者为观察组。比较两组治疗后的临床疗效，两组治疗前、后的黄斑区血流灌注参数\〖浅层毛细血管丛(SCP)血流密度、深层毛细血管丛(DCP)血流密度、黄斑中心凹厚度(CMT)\〗、视觉功能指标\〖最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(FT)、出血斑面积\〗以及治疗期间并发症发生情况。

结果：两组患者基线资料具有可比性。观察组的治疗总有效率(97%)明显高于对照组(83%)(P<0.05)； 治疗6 mo，两组SCP血流密度、DCP血流密度较治疗前均升高，且观察组高于对照组(均P<0.05)，两组CMT、BCVA值、FT、出血斑面积均减小，且观察组低于对照组(均P<0.05)； 治疗期间两组并发症总发生率比较无差异(P>0.05)。

结论：康柏西普联合SML治疗DME临床疗效显著，可改善黄斑区血流灌注和视觉功能，且具有良好的安全性。

METHODS: A retrospective analysis was conducted on 70 patients with DME admitted to our hospital from June 2023 to December 2024. Based on their treatment regimens, the patients were divided into two groups: 35 patients receiving anti-VEGF monotherapy served as the control group, and 35 patients receiving combined conbercept and SML therapy comprised the observation group. The clinical efficacy, macular perfusion parameters \〖superficial capillary plexus(SCP)vessel density, deep capillary plexus(DCP)vessel density, central macular thickness(CMT)\〗, visual function metrics \〖best-corrected visual acuity(BCVA), foveal thickness(FT), hemorrhagic spot area\〗, and the incidence of complications during treatment were compared between the two groups before and after treatment.

RESULTS:The baseline data of the two groups were comparable. The total effective rate was significantly higher in the observation group than in the control group(97% vs 83%, P<0.05). At 6 mo after treatment, SCP and DCP vessel densities increased in both groups compared to pre-treatment levels, with greater improvements observed in the observation group(all P<0.05). Conversely, CMT, BCVA, FT, and hemorrhagic spot area decreased in both groups, with more significant reductions in the observation group(all P<0.05). No statistically significant difference was found in the incidence of complications between the two groups during the treatment period(P>0.05).

CONCLUSION: The combination of conbercept and SML therapy demonstrates significant clinical efficacy in treating DME. It effectively improves macular blood perfusion and visual function with a favorable safety profile.